Approaches to the treatment of schizophrenia were recently reviewed by Darryle Schoepp, PhD, Senior Vice President of Merck & Co in a video interview with Greg Rose of Pharmexperts.com. According to Schoepp currently available drugs for the treatment of psychosis: "typical" and "atypical antipsychotics", are effective primarily against acute symptoms of the disease. Chronic cognitive symptoms are poorly controlled by the currently available drugs. Alternative therapy is needed. Schoepp is proposing to develop agonists of glutamate receptors as a new therapy of schizophrenia. These drugs are effective in animal models of psychosis and are likely to improve cognitive function. Their clinical effectiveness has not yet been established. The video interview with Dr. Schoepp can be viewed here (see below). It is also available on http://www.SciVeee.com/ .
Keywords: psychosis - schizophrenia - antipsychotics - cognition - cognitive symptoms - animal models - pharmexperts - neuroprotective drugs - glutamate receptors agonists - Darryle Schoepp-Merck & Co -Greg Rose.
